Director Lange sold 44,619 shares (81.2% of holdings) at $30.42 avg; stock down 28.1% from 52-week high, revenues fallen 50.6%.
Louis G. Lange, a Director, executed 2 separate sales totaling 44,619 shares for $1,357,229.51, reducing his holding from 54,979 shares to 10,360 shares—a reduction of 81.2%. The sales occurred at blended average price of $30.42, above the current price of $29.82 but notably below the 52-week high of $41.45. NewAmsterdam Pharma is trading 28.1% below its 52-week peak, with revenue declining 50.6% year-over-year and the company reporting a net loss of $72,005,000 in its most recent full fiscal year. While Lange's cross-ticker track record shows 100% 90-day win rate on prior buys, his single prior trade at NAMS in February 2024 resulted in a 6.4% 90-day return, providing limited predictive value for sell-side timing at this specific security. The near-complete liquidation of his NAMS position warrants investor attention given the company's deteriorating operational metrics and depressed valuation context.